(Q38180157)

30 August 2017

Established and novel disease-modifying treatments in multiple sclerosis (English)

1 reference

30 August 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444048%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

R T Naismith

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444048%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

11 March 2014

1 reference

Journal of Internal Medicine

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444048%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444048%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444048%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

350-363

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444048%20AND%20SRC:MED&resulttype=core&format=json

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Monoclonal antibodies in MS: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Fingolimod is a potential novel therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Dimethyl fumarate - only an anti-psoriatic medication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

New and emerging disease modifying therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Remyelination protects axons from demyelination-associated axon degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

LINGO-1 negatively regulates myelination by oligodendrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Autologous haematopoietic-stem-cell transplantation for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12203